MINERVA NEUROSCIENCES INC (NERV) — insider trading
Health Care · NASDAQ
MINERVA NEUROSCIENCES INC (NERV) has 12 reported SEC Form 4 insider transactions in our data (latest 2026-08-03).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-03 | Kaul Inderjit | Director | Grant / award / vesting (derivative) | 12,147 | — | $0 | Form 4 |
| 2026-06-03 | HASLER HANS PETER | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-03 | VAN HEEK G JAN | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-03 | Kaul Inderjit | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-03 | Kupfer David | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-03 | Laghrissi-Thode Fouzia | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-06-03 | Luthringer Remy | Director, Officer (CEO) | Grant / award / vesting (derivative) | 1,690,700 | — | $0 | Form 4 |
| 2026-06-03 | Ahlholm Frederick W | Officer (SVP, CFO and Secretary) | Grant / award / vesting (derivative) | 680,000 | — | $0 | Form 4 |
| 2026-04-21 | O'Connor James Joseph | Officer (Chief Business Officer and GC) | Grant / award / vesting (derivative) | 350,800 | — | $0 | Form 4 |
| 2026-03-31 | Kaul Inderjit | Director | Grant / award / vesting (derivative) | 12,169 | — | $0 | Form 4 |
| 2025-12-22 | Kaul Inderjit | Director | Grant / award / vesting (derivative) | 364,504 | — | $0 | Form 4 |
| 2025-12-22 | Kupfer David | Director | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
Ask the chat about NERV's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MINERVA NEUROSCIENCES INC (NERV).
Last updated 2026-08-03 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.